19 ．Aids Research Center

Different vaccine vectors delivering the same antigen
elicit CD8+ T cell responses with distinct clonotype and1)

Jeong SJ, Ryo A, Yamamoto N: The prolyl isomerase
Pin1 stabilizes the human T-cell leukemia virus type 12)

5)

K,PinyosukheeN,294-299, 2009.

Mycobacterium bovis BCG and recombinant vaccinia

Nishi M, Ryo A, Tsurutani N, Ohba K, Sawasaki T,virus DIs harboring HIV-1 CRF01_AE gag in mice:

Morishita R, Perrem K, Aoki I, Morikawa Y, Yamamoto

influence of immunization routes. Southeast Asian J Trop

N: Requirement for microtubule integrity in theMed Public Health 40: 273-281, 2009.
10) Land S, Cunningham P, Zhou J, Frost K, Katzenstein D,FEBS Lett 583(8): 1243-1250, 2009.

Kantor R, Chen YM, Oka S, DeLong A, Sayer D, Smith

Ohba K, Ryo A, Dewan MD, Nishi M, Naito T, Qi X,J, Dax EM, Law M; TAQAS Laboratory Network.

Inagaki Y, Okamoto T, Terashima K, Yamamoto N:TREAT Asia Quality Assessment Scheme (TAQAS) toFollicular dendritic cells activate HIV-1 replication instandardize the outcome of HIV genotypic resistancemonocytes/macrophages through a juxtacrine mechanism

testing in a group of Asian laboratories. J Virol Methods

mediated by P-selectin glycoprotein ligand-1. J Immunol

159(2): 185-193, 2009.
11) Hasegawa N, Sugiura W, Shibata J, Matsuda M, Ren F,

Murakami T, Eda Y, Nakasone T, Ami Y, Someya K,Tanaka H: Inferring within-patient HIV-1 evolutionary

Yoshino N, Kaizu M, Izumi Y, Matsui H, Shinohara K,

dynamics under anti-HIV therapy using serial virus

Yamamoto N, Honda M: Postinfection passive transfer ofsamples with vSPA. BMC Bioinformatics 10(1): 360,

KD-2472009.

protects

againstsimian/humanimmunodeficiency virus-induced CD4+ T-cell loss in12) Iwatani Y, Chan DS, Liu L, Yoshii H, Shibata J,

macaque lymphoid tissue. AIDS 23(12): 1485-1494,

Yamamoto N, Levin JG, Gronenborn AM, Sugiura W:

2009.

HIV-1

Zhou W, Yang Q, Low CB, Karthik BC, Wang Y, Ryo A,

APOBEC3G involves four critical lysine residues in its

Yao

C-terminal domain. Proc Natl Acad Sci U S A, 106(46):

SQ,YangD,Liou

YC:Pin1

catalyzes

Vif-mediatedubiquitination/degradationof19539-19544, 2009.
13) Fujisaki S, Yokomaku Y, Hattori J, Ibe S, Utsumi M,

process. J Biol Chem 284(36): 23980-23988, 2009.

Hamaguchi M, Iwatani Y Sugiura W: Molecular

Miyakawa K, Ryo A, Murakami T, Ohba K, Yamaoka S,

epidemiology of HBV-HIV-1 coinfection in Japan.

Fukuda M, Guatelli J, Yamamoto N: BCA2/Rabring7

Antivir Ther 14 Suppl 1: A67, 2009.

promotes tetherin-dependent HIV-1 restriction. PLoS8)

MatsuoWarachit P. Prime-boost vaccination using recombinant

mediates its stability through a polyubiquitination

7)

D,transformation. Biochem Biophys Res Commun 381(2):conformational changes of Thr-187 in p27Kip1 and6)

Promkhatkaew

Thongdeejaroen W, Leang-Aramgul P, Sawanpanyalert P,

183(1): 524-532, 2009.
4)

9)(HTLV-1) Tax oncoprotein and promotes malignant

SOCS1-mediated intracellular dynamics of HIV-1 Gag.

3)

epitope specificity. J Immunol 183: 2425-2434, 2009.

14) Hattori J, Yoshida S, Ito T, Gatanaga H, Kondo M,Pathog 5(12): e1000700, 2009.

Sadamasu K, Kato S, Tanabe Y, UedaＭ, Shirasaka T,Ryo A, Wulf G, Lee TH, Lu KP: Pinning down HER2-ER

Mori H, Minami R, Sugiura W, the Japanese Drugcrosstalk in SMRT regulation. Trends Biochem Sci 34(4):Resistance HIV-1 Surveillance Net Work: Increasing

162-165, 2009.

prevalence

Honda M, Wang R, Kong WP, Kanekiyo M, Akahata W,

treatment-naïve HIV-infected patients in Japan fromXu L, Matsuo K, Natarajan K, Robinson H, Asher TE,

2003 to 2008. Antivir Ther 14 Suppl 1: A78, 2009.

Price DA, Douek DC, Margulies DH, Nabel GJ:15) Fujino M, Miura H, Hattori J, Ibe S, Fujisaki S, Matsuda
1ofdrug-resistancemutationsamong

M, Nishizawa M, Iwatani Y, Sugiura W: Machanism ofclone

darunavir(CRF33_01B). PLoS One 4(8): e6666, 2009.

resistanceacquisition

inmulti-proteaseinhibitor resistant HIV-1. Antivir Ther 14 Suppl 1: A113,ofaHIV-1

circulating

recombinant

form24) Murakami T, Kumakura S, Yamazaki T, Tanaka R,

2009.

Hamatake M, Okuma K, Huang W, Toma J, Komano J,16) Kondo M, Sudo K, Tanaka R, Sano T, Sagara H,Yanaka M, Tanaka Y, Yamamoto N: The novel CXCR4Iwamuro S, Takebe Y, Imai M, Kato S: Quantitation ofantagonist KRH-3955 is an orally bioavailable andHIV-1 group M proviral DNA using TaqMan MGB

extremely potent inhibitor of human immunodeficiency

real-time PCR. J Virol Methods 157 (2): 141-146, 2009.

virus17) Tee KK, Takebe Y, Kamarulzaman A: Emerging andAMD3100.

re-emerging viruses in Malaysia, 1997-2007. Int J Infect
Dis 13(3): 307-318, 2009.

type1

infection:

Antimicrob

comparative
Agentsstudies

Chemotherwith53(7):2940-2948, 2009.
25) Fuji H, Urano E, Futahashi Y, Hamatake M, Tatsumi J,18) Tee KK, Pybus OG, Parker J, Ng KP, Kamarulzaman A,

Hoshino T, Morikawa Y, Yamamoto N, Komano J:Takebe Y: Estimating the date of origin of an HIV-1

Derivatives

circulating recombinant form. Virology 387 (1): 229-234,

carbamoylmethyl

2009.

associated with HIV-1 reverse transcriptase. J Med Chem

19) Tanaka R, Tsujii H, Yamada T, Kajimoto T, Amano F,Hasegawa J, Hamashima Y, Node M, Katoh K, Takebe Y:of5-nitro-furan-2-carboxylicester

inhibit

RNaseHacid
activity

52(5): 1380-1387, 2009.
26) Hamatake M, Aoki T, Futahashi Y, Urano E, Yamamoto

Novel 3alpha-methoxyserrat-14-en-21beta-ol (PJ-1) andN,

3beta-methoxyserrat-14-en-21beta-ol

multimerization(PJ-2)-curcumin,

KomanoJ:

Ligand-independentofCXCR4,

ahigher-orderG-protein-coupledkojic acid, quercetin, and baicalein conjugates as HIV

chemokine receptor involved in targeted metastasis.

agents. Bioorg Med Chem 17(14): 5238-5246, 2009.

Cancer Sci 100(1): 95-102, 2009.

20) Liao H, Tee KK, Hase S, Uenishi R, Li XJ, Kusagawa S,27) Iwasaki Y, Akari H, Murakami T, Kumakura S,Thang PH, Hien NT, Pybus OG, Takebe Y: Phylodynamic

Dewan Z, Yanaka M, Yamamoto N: Efficient

analysis of the dissemination of HIV-1 CRF01_AE ininhibition of SDF-1α-mediated chemotaxis andVietnam. Virology 391: 51-56, 2009.

HIV-1 infection by novel CXCR4 antagonists.
Cancer Sci 100: 778-781, 2009.

21) Delviks-Frankenberry KA, Nikolenko GN, Maldarelli F,
HaseS, TakebeY,

Pathak VK:

Subtype-specific28) Pereira LE, Onlamoon N, Wang X, Wang R, Li J,

differences in the HIV-1 reverse transcriptase connection

Reimann KA, Villinger F, Pattanapanyasat K, Mori K,

subdomain of CRF01_AE are associated with higher

Ansari AA: Preliminary in vivo efficacy studies of alevels of resistance to 3’-azido-3’-deoxythymidine. J Virol

recombinant

83(17): 8502-8513, 2009.

antibody. Cell Immunol 259: 165-176, 2009.

rhesusanti-alpha(4)beta(7)monoclonal22) Hassan R, Suzu S, Hiyoshi M, Takahashi-Makise N, Ueno29) Nonaka M, Uota S, Saitoh Y, Takahashi M, Sugimoto H,T, Agatsuma T, Akari H, Komano J, Takebe Y, Motoyoshi

Amet T, Arai A, Miura O, Yamamoto N, Yamaoka S:K, Okada S: Dys-regulated activation of a src tyroine

Role for protein geranylgeranylation in adult T-cellkinase Hck at the golgi disturbs N-glycosylation of aleukemia cell survival. Exp Cell Res 315(2): 141-150,cytokine receptor Fms. J Cell Physiol 221(2): 458-468,

2009.

2009.

30) Barnor JS, Habu Y, Yamamoto N, Miyano-Kurosaki N,23) Tee KK, Kusagawa S, Li XJ, Onogi N, Isogai M, Hase S,Ishikawa K, Yamamoto N, Takaku H: Inhibition ofUenishi R, Liao H, Kamarulzaman A, Takebe Y: Isolation

HIV-1 replication by long-term treatment with a chimericand characterization of a replication-competent molecular2

RNA containing shRNA and TAR decoy RNA. Antiviralprotease

Res 83: 156-164, 2009.

factor-kappaB and inhibits the tumor growth and31) Ono Y, Terashima K, Liu A, Yokoyama M, Yokoshima

inhibitor,ritonavirtargets

thenuclear

infiltration of EBV-positive lymphoblastoid B cells. Int JK, Mizukami M, Watanabe K, Mochimaru Y, Furusaka T,

Cancer 124(3): 622-629, 2009.

Shimizu N, Yamamoto N, Ishiwata T, Sugisaki Y, Yagi39) Tsutsumi H, Nomura W, Abe S, Mino T, Masuda A,T, Naito Z: Follicular dendritic cell sarcoma with

Ohashi N, Tanaka T, Ohba K, Yamamoto N, Akiyoshi K,

microtubuloreticular structure and virus-like particle

Tamamura H: Fluorogenically active leucine zipper

production in vitro. Pathol Int 59(5): 332-344, 2009.

peptides as tag-probe pairs for protein imaging in living32) Kamiyama H, Yoshii H, Tanaka Y, Sato H, Yamamoto N,cells. Angew Chem Int Ed Engl 48(48): 9164-9166,

Kubo Y: Raft localization of CXCR4 is primarily
required for X4-tropic human immunodeficiency virus

2009.
40) Saitoh T, Fujita N, Hayashi T, Takahara K, Satoh T, Lee H,

type 1 infection. Virology 386(1): 23-31, 2009.

Matsunaga K, Kageyama S, Omori H, Noda T, Yamamoto33) Kobayashi S, Wada A, Shibasaki S, Annaka M, Higuchi

N, Kawai T, Ishii K, Takeuchi O, Yoshimori T, Akira S:H, Adachi K, Mori N, Ishikawa T, Masuda Y, Watanabe

Atg9a controls dsDNA-driven dynamic translocation ofH, Yamamoto N, Yamaoka S, Inamatsu T: Spread of a

STING and the innate immune response. Proc Natl Acadlarge plasmid carrying the cpe gene and the tcp locus

Sci USA 106(49): 20842-20846, 2009.

amongstClostridiumfrom41) Matsuyama S, Aydan A, Ode H, Hata M, Sugiura W,ofHoshino T: Structural and energetic analysis on thegastroenteritis in a geriatric hospital. Epidemiol Infectcomplexes of clinically isolated subtype C HIV-1

137(1): 108-113, 2009.

proteases and approved inhibitors by molecular dynamics

nosocomial

perfringens

outbreaks

andisolates

sporadiccases

34) Suzuki H, Kidokoro M, Fofana IB, Ohashi T, Okamura T,
Matsuo K, Yamamoto N, Shida H:

Immunogenicity ofnewly

vaccinia

constructedattenuatedsimulation. J Phys Chem B 114(1): 521-530, 2010.
42) Nakahara T, Nomura W, Ohba K, Ohya A, Tanaka T,strain

Hashimoto C, Narumi T, Murakami T, Yamamoto N,

LC16m8Delta that expresses SIV Gag protein. Vaccine

Tamamura H: Remodeling of dynamic structures of27: 966-971, 2009.

HIV-1 envelope proteins leads to synthetic antigen35) Yajima M, Imadome K, Nakagawa A, Watanabe S,

molecules inducing neutralizing antibodies. Bioconjugate

Terashima K, Nakamura H, Ito M, Shimizu N, Honda M,
Yamamoto N, Fujiwara S.

Chem, 21(4): 709-714, 2010.

T-cell-mediated control of43) Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A,

Epstein-Barr virus infection in humanized mice. J InfectTong CY, Takebe Y, Pybus OG: Evolutionary genetics ofDis 200(10): 1611-5, 2009.

human enterovirus 71: origin, population dynamics,

36) Tomita M, Dewan MZ, Yamamoto N, Kikuchi A, Mori N.

natural selection, and seasonal periodicity of the VP1

Epstein-Barr virus-encoded latent membrane protein 1
activates beta-catenin signaling in B lymphocytes.Cancergene. J Virol, 84(7): 3339-3350, 2010.
44) Han X, Dai D, Zhao B, Liu J, Ding H, Zhang M, Hu Q, Lu

Sci 100(5): 807-812, 2009.

C, Goldin M, Takebe Y, Zhang L, Shang H: Genetic and37) Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S,

epidemiologic characterization of HIV-1 infection InYamamoto N, Toi M. Natural killer activity ofLiaoning Province, China. J Acquir Immune Defic Syndr

peripheral-blood mononuclear cells in breast cancer

53 Suppl 1: S27-33, 2010.

patients. Biomed Pharmacother 63(9): 703-706, 2009.

45) Haga S, Nagata N, Okamura T, Yamamoto N, Sata T,38) Dewan MZ, Tomita M, Katano H, Yamamoto N, Ahmed S,Yamamoto N, Sasazuki T, Ishizaka Y: TACE antagonists

Yamamoto M, Sata T, Mori N, Yamamoto N. An HIV

blocking ACE2 shedding caused by the spike protein of3

SARS-CoV are candidate antiviral compounds. Antiviral
Res 85(3): 551-555, 2010.
46) Li Y, Tee KK, Liao H, Hase S, Uenishi R, Li X-J,
Tsuchiura T, Yang R, Govindasamy S, Yong YK, Tan HY,Pybus OG, Kamarulzaman A, Takebe, Y: Identification ofa novel second-generation circulating recombinant form(CRF48_01B) in Malaysia: a descendant of the previously
identified CRF33_01B. J Acquir Immune Defic Syndr, inpress.
47) Li Y, Uenishi R, Hase S, Liao H, Li X-J, Tsuchiura T, Tee
KK, Yang R, Pybus OG, Takebe Y: Explosive HIV-1
subtype B' epidemics in Asia driven by geographic andrisk group founder events. Virology, in press.
48) Naruse TK, Chen Z, Yanagida R, Yamashita T, Saito Y,Mori K, Akari H, Yasutomi Y, Miyazawa M, Matano T,Kimura A: Diversity of MHC class I genes inBurmese-origin rhesus macaques. Immunogenetics, inpress.
49) Takada M, Terunuma H, Deng X, Dewan MZ, Saji S,Kuroi K, Yamamoto N, Toi M: Refractory lung metastasis
from breast cancer treated with multidisciplinary therapy
including an immunological approach. Breast Cancer, inpress.

4